

#### CWMD/MCDC Other Transactions CBDAIF UPDATE

#### PROTECTING THE JOINT FORCE

UNCLASSIFIED Distribution Statement A: Approved for public release; distribution is unlimited.

Mr. Jeff Megargel 15 August 2019 Joint Program Executive Officer for Chemical, Biological, Radiological and Nuclear Defense

#### AGENDA

- Background
- CWMD OT Workload
- MCDC Workload
- OT Lessons Learned
- The Basket Provision
- Transitioning to Follow-on Production
- Significant Events
- What's Coming



## BACKGROUND


The JPEO-CBRND sponsors two consortium based other transaction agreements.

- Medical CBRN Defense Consortium (MCDC)
  - Estimated ceiling of \$10B with 20 year PoP
  - Established May 2016
- Countering Weapons of Mass Destruction (CWMD)
  - Estimated ceiling of \$10B with ten year PoP
  - Established November 2017
- Both other transactions are scoped to fulfill CWMD / CBRNE prototyping requirements for any Federal agency with OT authority.




The MCDC has awarded 26 prototyping projects and the CWMD OT has awarded 57.

## **CWMD OT WORKLOAD BREAKDOWN**



#### FY18 Workload by Customer



Total Projects: 22


**Total Projects: 95** 

Workload increased by <u>231</u>% from FY18 to FY19 External Organizations account for over <u>40</u>% of workload <u>12</u> additional projects are projected for FY19



UNCLASSIFIED

#### **MCDC OT WORKLOAD BREAKDOWN**



# **OT Lessons Learned & Best Practices**

- DoD now emphasizing insertion of logistics concerns into OT prototyping phase agreement scope
  - Evolving approach to ensure logistics support will be in scope for follow-on
- Industry can elect to use Fixed Amount or Expenditure Based pricing
  - Reporting should be appropriate to complexity of effort
- Deliverables / milestone schedule and intellectual property assertions must be aligned
  - PMO engaging in SOW negotiations to reduce time to approval
- Modifications happen



Initial scope for each agreement should be broad

# THE BASKET (IS IT JUST A MIRAGE?)

- Both JPEO-CBRND sponsored OTAs have a basket provision that allows any white paper proposals that were evaluated as acceptable to remain valid for up to 36 months.
  - Any DoD, HHS, or DHS user may "pull" a white paper out of the basket and begin negotiating the SOW.
    - Requires concurrence from original requirements office
    - One time use only
    - Assume PALT of 60 days (must be within 36 month window)



The CWMD OT has awarded five projects from the basket; MCDC has awarded three with five more in negotiation.

# **CWMD OT BASKET PULL ACTIVITY**

RPP	Project	Status				
RPP-18-01	CWMD1801-001	Awarded				
RPP-18-01	CWMD1801-004	Awarded				
RPP-18-06	CWMD1810-003	Awarded				
RPP-18-14	CWMD1817 <sup>1</sup>	Pre-Award				
RPP-18-21	CWMD1824-021	Awarded				
RPP-18-26	CWMD1829-003	Awarded				
<sup>1</sup> The CWMD 1817 basket pull will be awarded in FY19.						

UNCLASSIFIED

PROJE

## MCDC OT BASKET PULL ACTIVITY

RPP	Project	Status
17-01-02	17-01-02-004	Awarded
18-04-14	18-04-14-003	Awarded
18-04-14	18-04-14-007	Awarded
18-04-11	18-04-11-004	Pre-Award
18-04-13	18-04-13-002	Pre-Award
18-04-13	18-04-13-003	Pre-Award
18-06-17	18-06-17-001	Pre-Award
19-05	19-05-001	Pre-Award
19-05	19-05-007	Pre-Award



UNCLASSIFIED

#### **IS IT DIFFICULT TO OBTAIN FEEDBACK?**

- ATI automatically provides or makes available feedback (in BIDS) to the POC listed in the proposal or white paper regardless of selection decision.
  - The feedback letter is a verbatim copy of the evaluation of each proposal or white paper.
- When ATI receives requests for additional feedback, they refer each offeror to the AOR listed in the RPP.
  - On exceedingly rare occasions, the OT PMO has been asked to assist in coordinating provision of more detailed feedback.



*If an offeror experiences difficulty obtaining additional feedback, they need only contact ATI or the OT PMO for assistance.* 

## **Transitioning to Follow-On Production**

- JPEO-CBRND conducting initial planning for follow-on production
  - Most projects will use a FAR based approach
  - APG-EA planning to execute first stand-alone follow-on other transactions (FOT)
  - Will follow USD A&S requirements for determining eligibility for FOT
- As long as competitive procedures were utilized [for the prototype project], the participant successfully completed the prototype, and the solicitation and original agreement allowed for a follow-on for production contract or other transaction, a sole-source award may be made to a single participant. *USD A&S Other Transaction Guide, Section E.4.*, November 2018.





# **Significant Events**

- PMO consolidation effective 1 June 2019
  - MCDC and CWMD OTs managed in one PMO
- Combined general membership meeting scheduled for 12-13 November 2019 in Rockville, MD
  - Emphasizing collaboration between the DHS CWMD Office and the JPEO-CBRND
  - Will include DTRA, HHS and CCDC CB center among others
  - Tentative agenda includes OT related training, business opportunities and one-on-one sessions



# **What's Coming**

- Multiple prototyping projects will transition to follow-on production in FY20
  - Focused on smooth transition between contracting activities
  - Sorting out legal aspects and engagement with incumbents
- Increased focus on training and forecasting
  - FY19 training efforts have really paid off
  - Effective communication of opportunities is still work in progress
- Expand collaboration with DTRA and DHS CWMD Office

SPECTING THE JOHN TORCE

Anticipate changes in the usage rates associated with each OT consortium.

#### **POINTS OF CONTACT**

#### Thomas Dickson Chief Contracting Officer thomas.a.dickson4.civ@mail.mil

#### Michele Boardwine Director, JCMO michele.l.boardwine.civ@mail.mil

#### Jeff Megargel Program Manager 410.417.2323 jeffrey.w.megargel.civ@mail.mil

#### Barry Sayer Senior Contract Integrator 301.619.2709 barry.g.sayer.civ@mail.mil






# Backups





#### **CWMD PERFORMANCE**

#### Days to Award



RPP

#### **MCDC PERFORMANCE**

JpDM	RPP	Sub- Objective	Sub-Objective Area	PROJECT NAME (SUBOBJECTIVE)	FINAL COST Incl Fee	PALT
MCS	16-01	16-01	PREVENTION	Fill/Finish of VEE Virus like particle (BLP) Bulk Drug Product	\$699,102.54	169
MCS	16-01	16-01-02	PREVENTION	Development of Monoclonal Antibody MCS against Aerolized Botulinum Toxin Serotypes A and B	\$44,114,567.00	100
MCS	16-02	16-02-05	PREVENTION	VEE Monovalent VLP Phase I Clinical Study	\$5,208,172.41	203
MCS	16-02	16-02-03	TREATMENT	Development of a Dual Drug Agency Delivery Device (D4) AutoInjector	\$24,490,355.13	375
MCS	17-02	17-02-05	DETECTION	Man-Portable Diagnostics System (MPDS)	\$38,386,565.29	200
MCS	17-02	17-02-04	PREVENTION	Dev. Of Multiple Target Single Vector Vaccine Prototype against Aerosolized Equine Encephalitic viruses including VEE Virus	\$ 37,979,997.96	396
JSTO	18-01	18-01-03	PREVENTION	Late Discovery and Development of Therapeutics to Treat Symptoms of Exposure to Organophosphorus Chemical Warfare Nerve Agents	\$ 11,603,731.95	301
MCS	17-03	17-03-07	DETECTION	Man-Portable Diagnostics System (MPDS) - Expanded Scope	\$ 59,636,949.63	434
JSTO	18-04	18-04-15	DETECTION	Point-of-Care Diagnostics to identify the Causative Agents for Melioidosis and the Plague	\$ 4,694,645.80	144
MCS	18-02	18-02-04	TREATMENT	Large Animal Model Prototypes for Organophosphorus (OP) Nerve Agent (NA) Intoxication and Therapeutic Evaluations	\$ 249,496.80	245
MCS	17-03	17-03-08	DETECTION	Chemical Exposure In Vitro Diagnostics (Chem DX)	\$ 9,943,280.10	481
JSTO	18-04	18-04-15	DETECTION	Point-of-Care Diagnostics to identify the Causative Agents for Melioidosis and the Plague	\$ 1,359,270.40	172
JSTO	18-01	18-01-01	PREVENTION	Rapid Single-molecule-based Diagnostic platform Assessment of Pathogen Susceptibility to Anti-microbial Agent	\$ 3,488,708.88	411
JSTO	17-01	17-01-02	TREATMENT	Development of Efficacious Antiviral Countermeasures (EAC)	\$ 9,331,616.00	196
JSTO	18-01	18-01-01	PREVENTION	Rapid Single-molecule-based Diagnostic platform Assessment of Pathogen Susceptibility to Anti-microbial Agent	\$ 5,997,583.00	419
JSTO	18-06	18-06-16	TREATMENT	Novel Therapeutics for Multidrug Resistant Bacterial Bio threat Pathogens	\$ 8,894,774.00	344
JSTO	18-03	18-03-08	TREATMENT	Proof of Concept	\$ 2,236,389.00	388
JSTO	18-03	18-03-08	TREATMENT	Proof of Concept	\$ 1,940,766.00	388
JSTO	18-03	18-03-07	TREATMENT	Discovery and Development of New Therapeutics to Treat Symptoms of Exposure to Organophosphorus Chemical Warfare Nerve Agents	\$ 10,037,014.00	402
PRISM	18-05	18-05-19	PREVENTION	ADAMANT 2 Development of monoclonal antibodies as medical countermeasures against aerosolized Plague infection.	\$ 130,267,841.00	344
JSTO	18-04	18-04-10	DETECTION	Assay Development for the Identification of Markers of Venezuelan Equine Encephalitis Virus Infection in Animal Models	\$ 2,790,291.63	370
MCS	16-01	16-01	PREVENTION	Fill/Finish of VEE Virus like particle (BLP) Bulk Drug Product	\$699,102.54	169